Background. This study compared the risk of developing newonset diabetes between hemodialysis (HD) and peritoneal dialysis (PD) patients. We further investigated the effectiveness of icodextrin in reducing the risk of new-onset diabetes in PD patients. Methods. From the Taiwan health insurance database, 36 879 incident HD patients and 6382 incident PD patients from 2000 to 2010 were identified as study cohorts. We further selected an additional HD cohort matched by propensity scores (PSs) of PD patients. Incidence rates and hazard ratios (HRs) of newonset diabetes were assessed among cohorts and between icodextrin users and nonusers by the end of 2011. Results. For the unmatched cohorts, the incidence of new-onset diabetes was higher in PD patients than in HD patients (9.16 versus 8.18 per 1000 person-years), with an adjusted HR of 1.51 (95% CI 1.30-1.75) for PD patients. For the PS-matched cohorts, the corresponding incidence rates were 9.43 and 5.90 per 1000 person-years, respectively, with an adjusted HR of 1.61 (95% CI 1.32-1.97). Among PD patients, the incidence was lower in icodextrin users than in nonusers (6.22 versus 12.1 per 1000 person-years), with an adjusted HR of 0.66 (95% CI 0.50-0.88) for users. Conclusions. Our study suggests that PD patients are at a higher risk of developing new-onset diabetes than HD patients. Icodextrin is recommended for PD patients to reduce the risk of new-onset diabetes.
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I N T R O D U C T I O N
Diabetes mellitus is a rapidly growing and serious health problem worldwide associated high subsequent complications and mortality, accounting for >40% of patients starting renal replacement therapy [1] . Dialysis patients with diabetes have a poorer prognosis than those without diabetes [1] . Risk factors for diabetes include older age, non-Caucasian populations, obesity, insulin resistance, hypertension, physical inactivity and chronic inflammation [2] [3] [4] .
Insulin resistance and concurrent hyperinsulinemia may present in all chronic kidney disease (CKD) stages, even in patients with normal glomerular filtration rate, irrespective of the type of renal disease, and may worsen the disease [5] [6] [7] [8] [9] [10] . The dialysis therapy can partially improve insulin resistance, but not to the normal level [9] . Glucose-based dialysate is the most commonly used solution in patients receiving peritoneal dialysis (PD), resulting in 100-300 g of glucose absorption via the peritoneal cavity per day [11] . Therefore PD patients may be at a greater risk of insulin resistance and new-onset diabetes than hemodialysis (HD) patients due to exposure to glucosebased solutions for therapy [12] . On the other hand, it has been reported that icodextrin, a glucose-sparing solution, has beneficial effects on reducing insulin resistance in nondiabetic PD patients [13, 14] . Studies assessing the risk of new-onset diabetes in dialysis patients are limited [15] [16] [17] . The aim of this study was to evaluate the risk of new-onset diabetes in HD and PD patients, using the claims data of Taiwan National Health Insurance. We also evaluated the new-onset diabetes risk for icodextrin users and nonusers among PD patients.
M A T E R I A L S A N D M E T H O D S

Data source
The National Health Insurance program of Taiwan was established in 1995, covering >99% of 23.7 million residents of Taiwan [18] . The diagnoses of diseases in this database were coded using the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). Patient identifications in the database were scrambled to protect patient privacy. This study was performed in compliance with guidelines of the Declaration of Helsinki and was approved by the Research Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115). Informed consent was waived since we used an existing database.
Study population
Using the insurance claims database, new end-stage renal disease (ESRD) patients without a history of diabetes (code 250), !18 years of age and undergoing dialysis for >90 days were identified from 1 January 2000 to 31 December 2010. The first date of dialysis treatment was defined as the index date. Patients receiving dialysis for <90 days or receiving kidney transplantation before the index date were excluded. The dialysis modality was defined as the modality at day 90 after the first dialysis session. Patients were not censored if the dialysis modality changed later.
In addition, we further selected a subcohort of HD patients matched by the propensity score (PS) of the PD cohort at a ratio of 1:1. We used logistic regression to calculate the PS for each patient based on baseline variables, including age, sex and the year of dialysis initiation, and comorbidities of coronary artery disease (codes 410-413, 414.01-414.05, 414.8 and 414.9), stroke (codes 430-438), atrial fibrillation (code 427.31), hyperlipidemia (code 272), congestive heart failure (codes 428, 398.91 and 402.x1), hypertension (codes 401-405), obesity (code 278.0), impaired glucose tolerance (code 790.2) and gestational diabetes (codes 648.0 and 648.8) and the use of furosemide or bumetanide, steroids or statins.
All patients were followed up from the date of the first dialysis session to the occurrence of new-onset diabetes (code 250), withdrawal from the insurance program, renal transplantation, death or 31 December 2011.
Statistical analysis
The chi-square test and the independent t-test were used to test the difference for categorical variables and continuous variables, respectively, between cohorts. We used the Kaplan-Meier method to plot the curves of the diabetes-free proportion of the study cohorts and assessed differences between HD and PD cohorts by the log-rank test for both PS-matched and unmatched cohorts. We further calculated the incidence density of new-onset diabetes in each cohort. The Cox proportional hazards regression model was employed to calculate the hazard ratio (HR) of new-onset diabetes and 95% confidence intervals (CIs). In addition, the sub-HR (SHR) and 95% CI were also estimated to consider the competing risk of death.
For PD patients, demographic status and comorbidities were compared between those using icodextrin (Extraneal; Baxter Healthcare, Deerfield, IL, USA) for at least 1 month and nonusers. The incidence and HRs of new-onset diabetes were compared between users and nonusers. The uses of 4.25% hypertonic glucose dialysate and automated PD (APD) were included as covariates in the analyses. Patients who had received APD for at least 30 days during the follow-up period were defined as users. Data analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). The significance level was set at <0.05.
R E S U L T S
We identified 43 261 incident ESRD patients without a prior history of diabetes from 2000 to 2010; the mean age was 60.3 6 15.9 years and 51% of patients were female (Table 1) . Among them, 36 879 were HD patients and 6382 were PD patients. PD patients were younger, comprised of more women, had fewer comorbidities except for hypertension, obesity and gestational diabetes and were more likely to use steroids and statins than HD patients. The PS-matched PD and HD cohorts had similar sample sizes of 6177 and had similar distributions in demographic status, comorbidities and medication use. A total of 44.6% and 29.8% PD patients had ever used 4.25% hypertonic glucose dialysate and APD, respectively. Figure 1 shows that fewer PD patients were free of diabetes than in HD patients, with a difference of 3.33% between the unmatched cohorts or 2.89% between the PS-matched cohorts (P < 0.001). The incident diabetes rate was 1.12-fold greater in the PD cohort than the unmatched HD cohort (9.16 versus 8.18 per 1000 person-years) ( Table 2 ). The adjusted HR of developing diabetes was 1.51 (95% CI 1.30-1.75) for PD patients compared with HD patients after adjustment for age, gender, the year of dialysis initiation, comorbidities and medication use. In the PS-matched cohorts, the incident diabetes rate was 1.58-fold greater in PD patients than in HD patients (9.43 versus 5.90 per 1000 person-years) with an adjusted HR of 1.61 (95% CI 1.32-1.97). Table 2 shows the hazard rate of developing diabetes for dialysis patients, with consideration of the competing risk of death. The hazard rate remained greater for PD patients compared with HD patients in both unmatched cohorts [adjusted SHR 1.44 (95% CI 1.26-1.63)] and PS-matched cohorts [adjusted SHR 1.60 (95% CI 1.31-1.94)]. Table 3 shows that, compared with nonusers, icodextrin users were younger, comprised of more men, had a higher prevalence of hyperlipidemia and hypertension and were more likely to use furosemide or bumetanide, steroids, statins, 4.25% hypertonic glucose dialysate and APD than nonusers. The incidence of new-onset diabetes in icodextrin users was nearly half that in nonusers (6.2 versus 12.1 per 1000 person-years), with an adjusted HR of 0.66 (95% CI 0.50-0.88) for the unmatched cohort (Table 4) . Similar findings appeared in the PS-matched cohorts.
Diabetes and dialysis
D I S C U S S I O N
The present study demonstrated that the risk of new-onset diabetes in ESRD patients was greater in PD patients than in HD patients. The PD cohort had an adjusted HR of 1.61 relative to the PS-matched HD cohort. However, the hazard rate decreased for nearly 40% of PD patients using icodextrin solution compared with nonusers, shown in both PS-matched and unmatched data. These findings have not been previously reported. Woodward et al. [19] analyzed data from the United States Renal Data System (USRDS) from 1994 to 1998 and found an incidence of 6% per year for new-onset diabetes in dialysis patients on the kidney transplant waiting list. Based on data from the USRDS from 2000 to 2001, Salifu et al. [16] found an incidence of 20 per 1000 patient-years in HD patients after at least a 3-year follow-up. They also found that HD patients with new-onset diabetes had a higher risk of mortality than those without new-onset diabetes [16] . Szeto et al. [20] observed a high new-onset rate of hyperglycemia in Chinese dialysis patients after initiating PD therapy for 1 month. They also found that the mortality rate over the 3-year follow-up ranged from 6.3% to 33.3% for patients with fasting plasma glucose levels <100 mg/dL to >200 mg/dL, respectively [20] . Older age, higher body mass index and a higher C-reactive protein level are risk factors for new-onset diabetes and impaired glucose Adjusted for age, gender, the year (dialysis initiation, comorbidities of coronary artery disease, stroke, hyperlipidemia, atrial fibrillation, hypertension, congestive heart failure, obesity, impaired glucose tolerance, gestational diabetes) and the use of furosemide or bumetanide, steroids or statins. SD, standard deviation; cHR, crude hazard ratio; aHR, adjusted hazard ratio; aSHR, adjusted subhazard ratio. *P < 0.05, **P < 0.01, ***P < 0.001. tolerance in PD patients [21] . Findings among studies comparing new-onset diabetes risks between HD and PD are conflicting [15, 17] . Tien et al. [17] failed to observe a significant relationship between dialysis modality and new-onset diabetes risk. However, Chou et al. [15] recently reported a 54% greater incidence of new-onset diabetes in HD patients than in PD patients. The reason for the discrepancy is unclear. On the other hand, our study showed that PD was associated with a higher diabetes risk than was HD. We found similar results in both unmatched cohorts and PS-matched cohorts and after considering the competing risk of death. A cross-sectional study found that insulin resistance was not related to glucose absorption in PD patients without using 4.25% hypertonic dialysate [22] . An earlier Chinese study showed a significant association between the use of glucosebased solutions and an elevated prevalence of metabolic syndrome in nondiabetic PD patients [23] . However, 44.6% of PD patients had ever used 4.25% hypertonic solutions in the present study. The percentages of this prescription may be higher than those of other countries.
Icodextrin, a glucose polymer derived from cornstarch, is now a commonly used glucose-sparing solution [24] . The main indication for using icodextrin is to enhance ultrafiltration during a long dwell, mitigating uncontrolled fluid overload [25] . This solution can also confer a favorable metabolic effect with a positive impact on glycemic and dyslipidemia control [26] [27] [28] [29] [30] [31] . These beneficial effects of using icodextrin may contribute to better technique and patient survival in PD patients [32] [33] [34] . In a recent multicenter randomized controlled trial, de Moraes et al. [13] reported that the use of icodextrin improved insulin resistance in nondiabetic patients after a 90-day trial. Icodextrin has been available in Taiwan since March 2003. Based on the insurance system of Taiwan, icodextrin can be prescribed once daily for patients with diabetes and glycated hemoglobin >7.0%, requiring a 2.5% or 4.25% dextrose solution in more than half of daily exchanges, or with high or high-average peritoneal membrane transport. Our study demonstrated that the use of icodextrin could reduce the risk of new-onset diabetes in PD patients.
This study has the strength of using a large population to compare the subsequent risk of new-onset diabetes between HD and PD patients. Findings shown in the unmatched cohort study are affirmed by the PS-matched cohort study. However, the present study has several limitations. First, information on personal characteristics, such as body height, body weight and smoking habits, was unavailable in this database. Second, information on laboratory data such as C-reactive protein, residual renal function and dialysis adequacy was also unavailable. Hence these variables could not be adjusted for data analyses. However, our data analysis did include obesity as a covariate. In addition, the relationship between body mass index and diabetes is weaker in Asians than in Caucasians [35] . The insurance system audited the indication of dialysis and the quality of dialysis [18] . Thus the residual renal function at the start of dialysis might not be different between HD and PD patients and the adequacy was ensured. In addition, diuretic use, a marker of residual urine, was adjusted in the data analysis. Nephrologists and diabetologists diagnosed diabetes for dialysis patients using the criteria of the the American Diabetes Association, including the levels of glycated hemoglobin [36] . However, the primary use of the 75 g oral glucose tolerance test to diagnose diabetes is not routinely performed in Taiwan. In addition, glycated hemoglobin may be falsely elevated or decreased in dialysis patients [37, 38] . The diagnosis of diabetes based on fasting glucose levels in PD patients might be confounded if the fasting blood samples were taken with a glucose-containing solution or icodextrin in the abdomen. However, 956 of 1276 (75.6%) HD and 209 of 240 (87.1%) PD patients with new-onset diabetes received hypoglycemic medications when this disorder was diagnosed. Thus, although information on levels of plasma glucose and glycated hemoglobin was unavailable in the claims data, the diagnosis of diabetes was reliable. A previous study reported that the diabetes diagnosis, not specific to dialysis patients, is valid in the claims data [39] . Furthermore, selection bias may exist. We performed the PS-matched analyses to reduce the bias. However, PS analyses might be unable to overcome bias with the remaining unmeasured confounders [40] .
In conclusion, this study demonstrated that PD patients are at a higher risk of developing new-onset diabetes than HD patients. The use of icodextrin solution could reduce the risk for PD patients. Further prospective studies are necessary to confirm our findings. 
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